HLB PANAGENE Co. LTD.
KKRX:0462101,393.00
KRW
-1.00
(-0.07%)
ISIN
KR7046210001
Return %
Stock
S&P 500
1Y
-18.06
14.39
3Y
-59.86
81.42
5Y
-64.14
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- In-Geun Jang
- Full Time Employees
- 84
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Daejeon South Korea
- IPO Date
- Aug 16, 2000
- Website
- hlbpanagene.com
- Similar Companies
- Business
- HLB PANAGENE Co., Ltd. is a South Korea-based biotechnology and molecular diagnostics company that develops, manufactures, and commercializes peptide nucleic acid (PNA)-based in vitro diagnostic products and high-purity biomaterials for clinical and research applications. Founded in 2001 and headquartered in Daejeon, South Korea, the company operates as a key diagnostic subsidiary of the HLB Group, serving medical institutions, reference laboratories, academic research centers, and biopharmaceutical manufacturers across South Korea, the Asia-Pacific region, North America, and Europe. HLB PANAGENE provides an integrated portfolio of molecular diagnostic solutions and specialized synthesis services, comprising PANAMutyper diagnostic kits designed for ultrasensitive somatic mutation detection and circulating cell-free DNA (cfDNA) liquid biopsy analysis; PNAClamp real-time PCR mutation detection kits targeting critical oncology biomarkers including EGFR, KRAS, NRAS, BRAF, and PIK3CA for lung, colorectal, gastric, and thyroid cancers; infectious disease diagnostic test kits for human papillomavirus (HPV), sexually transmitted pathogens, and respiratory viruses; custom-manufactured PNA oligomers and high-purity PNA monomers utilized in gene regulation, antisense drug development, and biosensor technologies; and associated molecular biology reagents alongside automated diagnostic testing systems. In recent strategic developments, the company was acquired by an HLB Group-led consortium and officially changed its corporate name from Panagene Inc. to HLB PANAGENE Co., Ltd. to accelerate synergies with HLB Group's global anticancer therapeutics portfolio, particularly through the development of companion diagnostics (CDx). Additionally, the company has expanded its technological capabilities into next-generation sequencing (NGS) and artificial intelligence-integrated genomic analysis, secured regulatory clearances for novel cancer mutation panels, and established international distribution partnerships to expand its presence across overseas healthcare markets.